In 2008, PEP-3-KLH vaccine was first reported to induce newly diagnosed GBM patients to produce an EGFRvIII-specific antibody 81.EGFRvIII (type III epidermal growth factor receptor mutation), which is present in 24-67% of patients with GBM, allowing the continuous activation of EGFR 82. Here, EGFR is linked to glioblastoma.